Amphastar Pharmaceuticals (STU:29A) EPS (Basic): €1.47 (TTM As of Mar. 2026)

What is Amphastar Pharmaceuticals EPS (Basic)?

Amphastar Pharmaceuticals STU:29A +8.01% 79 EPS (Basic) is €1.47 as of Mar. 2026. GuruFocus rates STU:29A with a GF Score™ of 79/100 and a GF Value™ of €42.73 (Significantly Undervalued). The stock has 5 warning signs investors should review.

Amphastar Pharmaceuticals's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was €0.12. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was €1.47.

Amphastar Pharmaceuticals's EPS (Diluted) for the three months ended in Mar. 2026 was €0.12. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €1.43.

Amphastar Pharmaceuticals's EPS without NRI for the three months ended in Mar. 2026 was €0.36. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was 1.86.

During the past 12 months, Amphastar Pharmaceuticals's average EPS without NRIGrowth Rate was -39.30% per year. During the past 3 years, the average EPS without NRI Growth Rate was 18.20% per year. During the past 5 years, the average EPS without NRI Growth Rate was 39.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Amphastar Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 86.90% per year. The lowest was -31.00% per year. And the median was 30.10% per year.

Amphastar Pharmaceuticals (STU:29A) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Amphastar Pharmaceuticals EPS (Basic) Related Terms

Amphastar Pharmaceuticals EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Amphastar Pharmaceuticals's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amphastar Pharmaceuticals EPS (Basic) Chart

Amphastar Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EPS (Basic)

Get a 7-Day Free Trial

1.15

1.78

2.61

3.14

1.79

Amphastar Pharmaceuticals Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EPS (Basic)	Get a 7-Day Free Trial															0.49	0.57	0.32	0.45	0.12

79GF Score

Amphastar Pharmaceuticals Inc STU:29A

EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Amphastar Pharmaceuticals EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Amphastar Pharmaceuticals's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(83.772	-	0)	/	46.743
	=	1.79

Amphastar Pharmaceuticals's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(5.553	-	0)	/	45.322
	=	0.12

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.47

Frequently Asked Questions Learn more about EPS (Basic) →

What does a EPS (Basic) of €1.47 mean?

Amphastar Pharmaceuticals (STU:29A) has a EPS (Basic) of €1.47 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Amphastar Pharmaceuticals and its competitors.

Is Amphastar Pharmaceuticals' EPS (Basic) too high?

Amphastar Pharmaceuticals' current EPS (Basic) is €1.47. Overall, Amphastar Pharmaceuticals has a GF Score™ of 79/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Amphastar Pharmaceuticals' EPS (Basic) compare to ETON and ESPR?

Amphastar Pharmaceuticals' EPS (Basic) of €1.47 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EPS (Basic) for a Drug Manufacturers company?

A good EPS (Basic) depends on the Drug Manufacturers industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EPS (Basic) mean?

A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Amphastar Pharmaceuticals and its competitors. Amphastar Pharmaceuticals's current EPS (Basic) is €1.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Amphastar Pharmaceuticals stock overvalued right now?

Based on GuruFocus' analysis, Amphastar Pharmaceuticals (STU:29A) is currently considered Significantly Undervalued. The stock's GF Value™ is €42.73, compared to a current price of €18.41 — trading 56.9% below its estimated fair value. The current EPS (Basic) is €1.47. Amphastar Pharmaceuticals' overall GF Score™ is 79/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EPS (Basic) calculated?

EPS (Basic) is calculated from a company's financial statements. For Amphastar Pharmaceuticals (STU:29A), the current EPS (Basic) is €1.47 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Amphastar Pharmaceuticals (STU:29A) Overvalued in 2026?

Based on GuruFocus' analysis, Amphastar Pharmaceuticals stock appears to be undervalued. The current stock price of €18.41 is trading 56.9% below its estimated GF Value™ of €42.73. GuruFocus considers Amphastar Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for STU:29A:

EPS (Basic): €1.47
GF Value™: €42.73 vs. price of €18.41 (56.9% below fair value)
GF Score™: 79/100 with 5 warning signs

No single metric tells the full story. See the STU:29A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Amphastar Pharmaceuticals Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies ETON ESPR BIOA PCRX TLRY ALVO XERS IRWD COLL AQST XTER:MRK TSE:4502 XSWX:GALD SHSE:600276 NSE:SUNPHARMA XTAE:TEVA LSE:HLN XSWX:SDZ ZTS HKSE:03692

Other Exchanges AMPH:USA

Address 11570 6th Street, Rancho Cucamonga, CA, USA, 91730

Website https://www.amphastar.com

Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.

79GF Score

Get the complete analysis for STU:29A

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€18.41

Price

€42.73

GF Value

View STU:29A Analysis

See EPS (Basic) data for all stocks →